Evidence map›Paper›PMID 41028271›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

Computational Methods for Cancer Neoantigen Prediction.

Andrea Moreno-Manuel, Sotiris Ouzounis, Marius Eidsaa, Roberto Fornelino-González, Pilar Ballesteros-Cuartero, Daniel Gómez-Garrido, Esteban Veiga-Chacón, Theodora Katsila, Maurizio Callari, Arrate Muñoz-Barrutia and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Andrea Moreno-Manuel *Cancer Heterogeneity and Immunomics (CHI) Group, University Hospital Lozano Blesa, Aragon Health Research Institute (IISA), Zaragoza, Spain.
Sotiris Ouzounis *Institute of Chemical Biology, National Hellenic Research Foundation, Athens, Greece.
Marius Eidsaa *SINTEF Industry, Department of Biotechnology and Nanomedicine, P.O. Box 4760 Torgarden, Trondheim, Norway.
Roberto Fornelino-GonzálezCancer Heterogeneity and Immunomics (CHI) Group, University Hospital Lozano Blesa, Aragon Health Research Institute (IISA), Zaragoza, Spain.
Pilar Ballesteros-CuarteroDepartamento de Bioingenieria, Universidad Carlos III de Madrid, Leganés, Spain.
Daniel Gómez-GarridoCentro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Madrid, Spain.
Esteban Veiga-ChacónCentro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Madrid, Spain.
Theodora KatsilaInstitute of Chemical Biology, National Hellenic Research Foundation, Athens, Greece.
Maurizio CallariFondazione Michelangelo, Milan, Italy.
Arrate Muñoz-BarrutiaDepartamento de Bioingenieria, Universidad Carlos III de Madrid, Leganés, Spain.
Rebeca Sanz-PamplonaCancer Heterogeneity and Immunomics (CHI) Group, University Hospital Lozano Blesa, Aragon Health Research Institute (IISA), Zaragoza, Spain. rsanz@iisaragon.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neoantigens are mutated peptides arising from tumor genomic alterations, which can be recognized and attacked by the immune system, leading to antitumor immune responses. In the last decades, many immunotherapeutic strategies have been developed, which has increased the interest in neoantigens. This led to the development of computational tools that facilitate neoantigen identification and prioritization, prior to their validation using experimental approaches. This chapter aims at explaining the key steps that need to be conducted to identify potential neoantigens in silico, including an example of the most frequently used tools. This is followed by a description and comparison of the cutting-edge tools and pipelines for neoantigen prediction both for human and mouse. The last aim of this chapter is to depict the technical challenges that limit neoantigen prediction using bioinformatics, as well as the expected improvements, given the current revolution of artificial intelligence, which is implemented in most of the neoantigen-related tools. As exposed in this book chapter, we believe that advances in immunomics and computational biology will be key to implement personalized cancer immunotherapy in the clinical practice, to improve outcomes of cancer patients.

Indexed as

Antigens, NeoplasmComputational BiologyNeoplasmsAnimalsHumansImmunotherapyMiceAntigens, NeoplasmBioinformaticsCancerHLA-binding affinityImmune microenvironmentImmunomicsMHCMiceNeoantigen prediction

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.